Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will present Phase 3 data this month examining whether its experimental hypertension drug lorundrostat reduced both blood pressure and albuminuria in patients …
Mineralys Extends Lorundrostat Focus to Kidney Disease Read More
KING OF PRUSSIA, PA — Aclipse Therapeutics secured an option to acquire Cypress BioPharma, a deal that would expand its lead M107 drug candidate into childhood nephrotic syndrome and give …
Aclipse Targets Kidney Disease With Cypress Acquisition Option Read More RADNOR, PA — Mineralys Therapeutics (Nasdaq: MLYS) reported new Phase 3 data suggesting its experimental hypertension treatment lorundrostat may provide benefits for patients with chronic kidney disease, a finding that …
Mineralys Reports Kidney Disease Data Ahead of FDA Decision Read More